GlassScriptPhysician profile
Robyn Dawn Hartvickson
NPI 1679532659
$6,740.29
in general payments reported to CMS, 2019-2025
34 companies · $814 in 2025
The $814 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $259 · 2021: $868 · 2022: $1,013 · 2023: $2,574 · 2024: $862 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012 · Travel and Lodging: $1,224 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.09 |
| Travel and Lodging | $1,224.44 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $1,619.37 | 2023 | |
| Abbvie INC. | $1,253.64 | 2021-2025 | |
| Pfizer INC. | $723.15 | 2019-2025 | |
| Amgen INC. | $436.28 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $407.37 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $276.79 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $252.91 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $232.70 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $217.49 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $155.88 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $130.65 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $130.10 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $109.65 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $76.81 | 2020-2024 | |
| Eisai INC. | $74.67 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $74.42 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.09 | 2019-2024 | Jardiance, Tradjenta |
| Sunovion Pharmaceuticals INC. | $57.47 | 2022 | |
| Abbott Laboratories | $55.77 | 2021-2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.79 | 2022-2025 | Xifaxan |
| Allergan, INC. | $52.39 | 2019-2020 | |
| Amarin Pharma, INC. | $45.93 | 2019-2021 | |
| Exact Sciences Corporation | $42.37 | 2023 | Cologuard Collection Kit |
| Pacira Therapeutics, INC. | $41.19 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $38.82 | 2021-2022 | |
| Glaxosmithkline, LLC. | $36.80 | 2022-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $20.55 | 2021 | |
| Cranial Technologies, INC | $19.93 | 2025 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $16.91 | 2020 | |
| Radius Health, INC. | $12.09 | 2019 | |
| Mylan Specialty L.P. | $11.31 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Hartvickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.